RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells
Journal of Controlled Release · 2024-11 · 375 · 776-787
DOI: 10.1016/j.jconrel.2024.09.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-11. Verfasst von Nadia Rouatbi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, Lo…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Glioblastoma, Neoplastic Stem Cells, Nanoparticles. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain Research UK, Wellcome Trust, Brain Tumor Charity.
Abstract (Originalsprache)
In vitro and ex-vivo target identification strategies often fail to predict in vivo efficacy, particularly for glioblastoma (GBM), a highly heterogenous tumor rich in resistant cancer stem cells (GSCs). An in vivo screening tool can improve prediction of therapeutic efficacy by considering the complex tumor microenvironment and the dynamic plasticity of GSCs driving therapy resistance and recurrence. This study proposes lipid nanoparticles (LNPs) as an efficient in vivo CRISPR-Cas9 gene editing tool for target validation in mesenchymal GSCs. LNPs co-delivering mRNA (mCas9) and single-guide RNA (sgRNA) were successfully formulated and optimized facilitating both in vitro and in vivo gene editing. In vitro, LNPs achieved up to 67 % reduction in green fluorescent protein (GFP) expression, used as a model target, outperforming a commercial transfection reagent. Intratumoral administration of LNPs in GSCs resulted in ∼80 % GFP gene knock-out and a 2-fold reduction in GFP signal by day 14. This study showcases the applicability of CRISPR-Cas9 LNPs as a potential in vivo screening tool in GSCs, currently lacking effective treatment. By replacing GFP with a pool of potential targets, the proposed platform presents an exciting prospect for therapeutic target validation in orthotopic GSCs, bridging the gap between preclinical and clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK.
- Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK; Department of Pharmacology and Pharmacy, Li Ka Shing…
- Centre for Regenerative Medicine, Institute for Regeneration and Repair & Cancer Research UK Scotland Centre, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
Förderung
- Brain Research UK
- Wellcome Trust
- Brain Tumor Charity
Zitieren
APA
Rouatbi, N., Walters, A. A., Costa, P. M., Qin, Y., Liam-Or, R., Grant, V., Pollard, S. M., Wang, J. T., & Al-Jamal, K. T. (2024). RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells. Journal of Controlled Release, 375, 776-787. https://doi.org/10.1016/j.jconrel.2024.09.019
Vancouver
Rouatbi N, Walters AA, Costa PM, Qin Y, Liam-Or R, Grant V, et al. RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells. Journal of Controlled Release. 2024;375:776-787. doi:10.1016/j.jconrel.2024.09.019
BibTeX
@article{Rouatbi2024,
author = {Rouatbi, Nadia and Walters, Adam A and Costa, Pedro M and Qin, Yue and Liam-Or, Revadee and Grant, Vivien and Pollard, Steven M and Wang, Julie Tzu-Wen and Al-Jamal, Khuloud T},
title = {RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells},
journal = {Journal of Controlled Release},
year = {2024},
volume = {375},
pages = {776--787},
doi = {10.1016/j.jconrel.2024.09.019}
}
EUVIMED